Brantas Abipraya Builds Indonesia Gene Bank, Completed in 2027

JAKARTA - PT Brantas Abipraya (Persero) is building the Gene Bank Indonesia (National Genomics Bank) in the area of Dr. H. Marzoeki Mahdi Hospital (RSMM), Bogor City. The strategic project, which is targeted to be completed in 2027, is projected to become the largest genetic material storage and research center in Indonesia.

To ensure that construction is carried out according to target, the Brantas Abipraya Commissioner team conducted a Management Walkthrough by directly reviewing the progress of construction, work quality, and the implementation of aspects of Occupational Safety and Health (K3).

The activity was attended by the President Commissioner of PT Brantas Abipraya (Persero) Diana Kusumastuti, Independent Commissioners Isra D. Pramulya and Santoso, accompanied by Director of Operations II Mustafa Nahdi and SVP of Operations I Division Tintus Noviyanto.

During the review, the board of commissioners ensured that all construction work was carried out according to target while still prioritizing quality standards and work safety. This step is part of the company's commitment to maintaining good project governance while ensuring the timely completion of construction.

Corporate Secretary of PT Brantas Abipraya (Persero), Dian Sovana said the construction of the Indonesian Gene Bank has a higher level of complexity compared to the construction of conventional buildings.

Furthermore, Dian said that this was because the facility was designed to support the storage of genetic material, genomic research laboratories, to the processing of large-capacity data.

"This project not only requires high technical accuracy, but also the implementation of strict safety and environmental control systems to maintain the long-term stability of biological samples," Dian said in an official statement, Tuesday, June 23.

According to Dian, the Gene Bank Indonesia is planned to be built with a building area of 22,699 square meters and consists of eight floors. In fact, it is projected to become the largest genetic material storage and research center in Indonesia and the first in Southeast Asia.

In addition, the Gene Bank will also have facilities equipped with precision temperature and humidity control systems, layered security infrastructure, and information technology support that is capable of managing genomic big data in an integrated manner.

According to Dian, Brantas Abipraya's involvement in the project is a tangible proof of the company's support for the government's priority agenda in the health sector while strengthening the foundation of the national research and innovation ecosystem.

"Through this strategic project, Brantas Abipraya not only builds physical infrastructure, but also provides the foundation for the advancement of science and health for future generations," he said.

"We ensure that every stage of construction is carried out by prioritizing quality, work safety, and timeliness so that the benefits can be felt continuously by the Indonesian people," he continued.

Strategically, continued Dian, the presence of the Indonesian Gene Bank is expected to be an important foundation for strengthening the national health research and innovation ecosystem.

In addition to supporting the development of gene-based therapies and precision medicine, this facility will also strengthen national health data sovereignty while increasing Indonesia's competitiveness in the health and biotechnology sectors.

"Brantas Abipraya is proud to be part of this strategic project. We believe that the presence of Gene Bank Indonesia will strengthen the national health research and innovation ecosystem, as well as make Indonesia more ready to enter the era of precision medicine based on genomics," concluded Dian.